Neuralink Receives FDA Approval for Human Study: A Breakthrough in Brain Chip Technology
Neuralink, the brain-chip firm founded by Elon Musk, has achieved a significant milestone with the approval from the US Food and Drugs Administration (FDA) to conduct its inaugural human tests. The company aims to revolutionize the field by merging the capabilities of computers with the human brain to restore vision and mobility for individuals facing disabilities.
While Neuralink currently does not have immediate plans to begin recruiting participants, this achievement marks a pivotal moment in the company's journey. Previous attempts by Elon Musk to commence human trials were unsuccessful, but this recent approval shows progress in realizing the vision of Neuralink.
The FDA has not yet provided an
official statement regarding the approval, but earlier reports in March, citing former and current employees, mentioned that a prior application from Neuralink was rejected due to safety concerns.
Neuralink's primary objective is to leverage its microchips to address conditions such as paralysis and blindness, enabling disabled individuals to interface with computers and mobile technology. Through the use of these chips, which have already undergone testing on monkeys, signals produced by the brain can be interpreted and transmitted to external devices via Bluetooth connectivity.
Elon Musk has previously highlighted the potential of Neuralink's technology to alleviate concerns about humans being displaced by artificial intelligence (AI). The company's Twitter announcement
“ Stay ahead of the news with WSN TIMES. We delivers the latest, most accurate and relevant information on politics, business, sports, entertainment and more. Get informed, always. ”
emphasized the approval as an important first step towards helping numerous people, acknowledging the dedication of the Neuralink team and their collaboration with the FDA.
Neuralink assures that safety, accessibility, and reliability are key priorities during its engineering process. However, experts caution that extensive testing and resolution of technical and ethical challenges will be crucial before Neuralink's brain implants can be widely available.
Since its establishment in 2016, Neuralink has faced delays and revised timelines in executing its plans. Initially, the goal was to begin implanting chips in human brains by 2020, following a pledge made the previous year. However, the company later adjusted its timeline to commence
activities in 2022. Additionally, Neuralink encountered setbacks in December of the previous year, facing allegations of animal welfare violations. However, the company denied these claims.
Neuralink's recent disclosure regarding FDA approval for human testing comes in the wake of a significant advancement in brain implant technology achieved by researchers from Switzerland. Notably, a paralyzed individual from the Netherlands achieved the ability to walk through a wireless system of implants that transmit his thoughts to his legs and feet.
As the field of brain-computer interfaces progresses, Neuralink's achievement in obtaining FDA approval highlights the potential for groundbreaking advancements in restoring functionality and improving the lives of individuals facing neurological challenges.